Author Responses to Peer-Review Reports https://med.jmirx.org/2020/1/e24485/
Published Article https://med.jmirx.org/2020/1/e19583/
This is a peer review submitted for the paper “No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.”
Round 1 Review
Drug repurposing offers the chance to quickly move potentially effective drugs forward to treat COVID-19. The authors note that drug candidates should ideally have a track record of safety, affordability, and accessibility. The authors use the literature to support the use of four classes of generic drugs that target the pathophysiology of COVID-19: (1) the histamine H2 receptor antagonists cimetidine and famotidine; (2) the antiplatelet agent/phosphodiesterase inhibitor dipyridamole; (3) the phosphodiesterase-5 inhibitor sildenafil; and (4) the cholesterol-lowering agents fenofibrate and bezafibrate. These drugs are affordable and supported by decades of safety data. They also argue that this approach can be used to identify other drugs to address this urgent clinical need. The work is provocative and addresses a topic of great importance. Although it is generally well written, there are areas where this manuscript could be revised to improve clarity and readability, as outlined below.
The authors use many nonstandard abbreviations. Also, many of these are used only once or a few times. To improve readability, especially for this review article, please greatly reduce the number of abbreviations, especially nonstandard ones that are hardly used. Also, please make sure that all of your abbreviations are defined.
There are a few new papers in this rapidly evolving area that the authors may wish to include in this review. These are (1) cimetidine and famotidine: an ongoing RCT for famotidine (NCT04370262; https://pubmed.ncbi.nlm.nih.gov/32446698/); (2) dipyridamole: an observational study (NCT04424901); (3) sildenafil citrate: not yet recruiting (NCT04489446).
The abstract is a bit vague about the nature of the drugs used and the pathophysiology targeted. It would be important to mention the drug classes as well as (or instead of) the specific drugs of interest in the abstract. In addition, it would be helpful if the authors could mention some of the critical underlying pathophysiological mechanisms that these drugs target with respect to COVID-19 (eg, anti-inflammatory, antiviral, cardioprotective, etc).
As for the abstract, please refer to the drug classes as well as the specific drugs of interest.
Pathophysiology of COVID-19 section
In this section, it is not clear whether the authors mean inpatients or all affected individuals. In Table 1, it is easy to see fever in 79%-98% of all affected individuals, but it is more difficult to understand the 59% with sepsis refers to individuals in the community. Is this at presentation? These numbers need a better context. It would also be helpful to have references in the table.
Rearranging Table 1 would improve readability.
System, Clinical Finding, Prevalence, Reference
Respiratory Fever 79%-98% X
Cough 58%-79% X
Also, in this section, the authors refer to elevation of various plasma inflammatory biomarkers in COVID-19. Please list these, or the major ones. Alternatively, please clarify if they differ from what is listed in Table 1.
Potential Therapies Within the Current Pharmacopoeia Section
On page 4, in the sentence starting with “All three drugs…,” the authors argue the benefits of strategies that utilize the safest drugs with pleiotropic effects to treat COVID-19. This is an interesting and important point. However, this sentence is too long to be easily understood. Please revise and expand to clarify meaning.
Table 2: This table would be improved by the addition of specific references.
Page 3, top paragraph: The sentence starting with “Within the 200-400 mg…” needs a reference.
Page 4, second paragraph: For the sentence starting with “Examples include…,” please discuss/explain prednisolone and explain what is meant by “widening of the therapeutic window of glucocorticoid activity.”
The authors mention the ongoing phase 3 trial of sildenafil (100 mg daily for 14 days in patients with COVID-19 and give the trial number [NCT04304313]). It would be helpful to include trial numbers in Table 2.
The sentence beginning with “The efforts we make now to facilitate…” is really long and complex. It is hard to follow as written. Please clarify.
Please bold headings for Sildenafil and Fenofibrate / Bezafibrate for consistency.
Please be consistent with SARS-CoV—the V is not capitalized in all cases.
Page numbers are not sequential.
Conflicts of Interest
Edited by G Eysenbach; This is a non–peer-reviewed article. submitted 21.09.20; accepted 22.09.20; published 30.09.20Copyright
©Susan Howlett. Originally published in JMIRx Med (https://med.jmirx.org), 30.09.2020.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.